HUTCHMED (China) (HMDCF) Non-Current Deferred Tax Liability (2014 - 2025)
HUTCHMED (China) (HMDCF) reported Non-Current Deferred Tax Liability of $255000.0 for Q4 2025, down 91.47% year-over-year from $3.0 million in Q4 2024, and down 91.47% quarter-over-quarter from $3.0 million in Q4 2024.
HUTCHMED (China) (HMDCF) Non-Current Deferred Tax Liability (2014 - 2025) Analysis & Trends
HUTCHMED (China) (HMDCF) has 12 years of Non-Current Deferred Tax Liability data on file, last reported at $255000.0 in Q4 2025.
- Non-Current Deferred Tax Liability for Q4 2025 came in at $255000.0, down 91.47% year-over-year; the trailing twelve-month figure through Dec 2025 was $255000.0 (down 91.47% YoY), and the FY2025 annual result was $255000.0, down 91.47% from the prior year.
- Non-Current Deferred Tax Liability fell to $255000.0 in Q4 2025 per HMDCF's latest filing, from $3.0 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $3.0 million in Q4 2024 and troughed at $255000.0 in Q4 2025.
- A 5-year average of $2.0 million and a median of $2.7 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability surged 101.48% in 2024, then slumped 91.47% in 2025.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.8 million in 2021, then slipped by 1.99% to $2.7 million in 2022, then plunged by 45.24% to $1.5 million in 2023, then surged by 101.48% to $3.0 million in 2024, then tumbled by 91.47% to $255000.0 in 2025.
- Business Quant data shows HMDCF's Non-Current Deferred Tax Liability at $255000.0 in Q4 2025, $3.0 million in Q4 2024, and $1.5 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | HUTCHMED (China) | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 255,000.00 |
| Dec 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 2.99 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Dec 31, 2020 | 3.55 Mn |
| Dec 31, 2020 | 3.55 Mn |
| Dec 31, 2019 | 2.34 Mn |
| Dec 31, 2019 | 2.34 Mn |
| Dec 31, 2018 | 4.26 Mn |
| Dec 31, 2018 | 4.26 Mn |
| Dec 31, 2017 | 3.82 Mn |
| Dec 31, 2017 | 3.82 Mn |
| Dec 31, 2016 | 4.99 Mn |
| Dec 31, 2016 | 4.99 Mn |